Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Redox-sensitive proteins susceptible to S-nitrosylation represent a diverse group of proteins whose function, stability, and localization are regulated by the covalent attachment of a nitric oxide (NO) moiety to specific cysteine thiol groups [1.3.1, 1.3.5]. This post-translational modification, known as S-nitrosylation, acts as a molecular switch similar to phosphorylation, mediating a significant portion of NO's biological activity across various organ systems [1.3.2, 1.3.4]. Key targets within this class include enzymes like GAPDH and Caspase-3, receptors such as the NMDA receptor, and ion channels like the Ryanodine receptor [1.3.3, 1.4.1]. Dysregulation of the "S-nitrosoproteome"—either through excessive S-nitrosylation (nitrosative stress) or insufficient denitrosylation—is implicated in the pathogenesis of numerous conditions, including neurodegenerative diseases like Parkinson's and Alzheimer's, cardiovascular disorders, and cancer [1.3.2, 1.3.3]. Therapeutic strategies involve the use of NO donors to restore signaling or inhibitors of denitrosylases, such as S-nitrosoglutathione reductase (GSNOR), to maintain S-nitrosothiol levels [1.2.1, 1.3.2]. Recent advancements focus on "targeted S-nitrosylation" using small molecules like NMT5 to improve selectivity and reduce off-target effects [1.2.1]. However, a major challenge in targeting these proteins is the potential for non-specific nitrosylation, which can lead to systemic hypotension and oxidative damage [1.2.1, 1.4.2]. Monitoring S-nitrosothiol levels in biological fluids is currently being explored as a biomarker for disease progression and therapeutic efficacy [1.1.1, 1.3.3].
Drugs targeting this class primarily act as nitric oxide (NO) donors, which facilitate the covalent attachment of NO to cysteine thiols (S-nitrosylation), or as inhibitors of denitrosylases like GSNOR to prevent the removal of these modifications [1.2.1, 1.3.2].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Redox-sensitive proteins susceptible to S-nitrosylation (SNO-proteins).